⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for copanlisib hydrochloride

Every month we try and update this database with for copanlisib hydrochloride cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerNCT03939897
Anatomic Stage ...
Metastatic Brea...
Metastatic HER2...
Metastatic Horm...
Recurrent Breas...
Abemaciclib
Biopsy
Biospecimen Col...
Copanlisib Hydr...
Diagnostic Imag...
Echocardiograph...
Fulvestrant
Multigated Acqu...
18 Years - National Cancer Institute (NCI)
Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast CancerNCT04345913
Anatomic Stage ...
Anatomic Stage ...
Metastatic Trip...
Unresectable Tr...
Biopsy
Biospecimen Col...
Computed Tomogr...
Copanlisib Hydr...
Eribulin Mesyla...
Magnetic Resona...
18 Years - National Cancer Institute (NCI)
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyNCT05295589
Platinum-Refrac...
Platinum-Refrac...
Platinum-Refrac...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Plati...
Recurrent Plati...
Recurrent Plati...
Recurrent Prima...
Recurrent Prima...
Computed Tomogr...
Copanlisib Hydr...
Magnetic Resona...
Olaparib
Paclitaxel
Pegylated Lipos...
Topotecan Hydro...
18 Years - National Cancer Institute (NCI)
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyNCT05295589
Platinum-Refrac...
Platinum-Refrac...
Platinum-Refrac...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Plati...
Recurrent Plati...
Recurrent Plati...
Recurrent Prima...
Recurrent Prima...
Computed Tomogr...
Copanlisib Hydr...
Magnetic Resona...
Olaparib
Paclitaxel
Pegylated Lipos...
Topotecan Hydro...
18 Years - National Cancer Institute (NCI)
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaNCT04939272
Recurrent Mantl...
Refractory Mant...
Copanlisib Hydr...
Venetoclax
18 Years - City of Hope Medical Center
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)NCT05490771
Advanced Lympho...
Advanced Malign...
Hematopoietic a...
Refractory Lymp...
Refractory Mali...
Refractory Mult...
Biopsy
Computed Tomogr...
Copanlisib Hydr...
Magnetic Resona...
18 Years - National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060
Advanced Lympho...
Advanced Malign...
Bladder Carcino...
Breast Carcinom...
Cervical Carcin...
Colon Carcinoma
Colorectal Carc...
Endometrial Car...
Esophageal Carc...
Gastric Carcino...
Glioma
Head and Neck C...
Hematopoietic a...
Kidney Carcinom...
Liver Carcinoma
Lung Carcinoma
Lymphoma
Malignant Uteri...
Melanoma
Multiple Myelom...
Ovarian Carcino...
Pancreatic Carc...
Prostate Carcin...
Rectal Carcinom...
Recurrent Bladd...
Recurrent Breas...
Recurrent Cervi...
Recurrent Colon...
Recurrent Color...
Recurrent Esoph...
Recurrent Gastr...
Recurrent Gliom...
Recurrent Head ...
Recurrent Liver...
Recurrent Lung ...
Recurrent Lymph...
Recurrent Malig...
Recurrent Melan...
Recurrent Multi...
Recurrent Ovari...
Recurrent Pancr...
Recurrent Prost...
Recurrent Recta...
Recurrent Skin ...
Recurrent Thyro...
Recurrent Uteri...
Refractory Lymp...
Refractory Mali...
Refractory Mult...
Skin Carcinoma
Thyroid Gland C...
Uterine Corpus ...
Adavosertib
Afatinib
Afatinib Dimale...
Binimetinib
Biopsy
Biospecimen Col...
Capivasertib
Computed Tomogr...
Copanlisib
Copanlisib Hydr...
Crizotinib
Cytology Specim...
Dabrafenib
Dabrafenib Mesy...
Dasatinib
Defactinib
Defactinib Hydr...
Echocardiograph...
Erdafitinib
Fexagratinib
Ipatasertib
Laboratory Biom...
Larotrectinib
Larotrectinib S...
Magnetic Resona...
Multigated Acqu...
Nivolumab
Osimertinib
Palbociclib
Pertuzumab
PI3K-beta Inhib...
Radiologic Exam...
Radionuclide Im...
Relatlimab
Sapanisertib
Sunitinib Malat...
Taselisib
Trametinib
Trastuzumab
Trastuzumab Emt...
Ulixertinib
Vismodegib
18 Years - National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsNCT03842228
Advanced Malign...
Metastatic Mali...
Unresectable Ma...
Biopsy
Biospecimen Col...
Computed Tomogr...
Copanlisib Hydr...
Durvalumab
Echocardiograph...
Magnetic Resona...
Olaparib
X-Ray Imaging
18 Years - National Cancer Institute (NCI)
Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast CancerNCT04345913
Anatomic Stage ...
Anatomic Stage ...
Metastatic Trip...
Unresectable Tr...
Biopsy
Biospecimen Col...
Computed Tomogr...
Copanlisib Hydr...
Eribulin Mesyla...
Magnetic Resona...
18 Years - National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsNCT03842228
Advanced Malign...
Metastatic Mali...
Unresectable Ma...
Biopsy
Biospecimen Col...
Computed Tomogr...
Copanlisib Hydr...
Durvalumab
Echocardiograph...
Magnetic Resona...
Olaparib
X-Ray Imaging
18 Years - National Cancer Institute (NCI)
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaNCT04939272
Recurrent Mantl...
Refractory Mant...
Copanlisib Hydr...
Venetoclax
18 Years - City of Hope Medical Center
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell LymphomaNCT03484819
Recurrent Diffu...
Recurrent Prima...
Refractory Diff...
Refractory Prim...
Copanlisib Hydr...
Nivolumab
18 Years - National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENNCT04317105
Advanced Malign...
Metastatic Mali...
Unresectable Ma...
Biopsy
Biospecimen Col...
Computed Tomogr...
Copanlisib Hydr...
Echocardiograph...
Ipilimumab
Nivolumab
X-Ray Imaging
18 Years - National Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: